No Detail Found!

Effectiveness and Safety of Sofosbuvir in Treatment-näive Children with Hepatitis C Infection.

Author(s)
Muhammad Almas Hashmi Department of Paediatric Gastroenterology and Hepatology, The Children's Hospital and The Institute of Child Health, Lahore, Pakistan
Huma Arshad Cheema Department of Paediatric Gastroenterology and Hepatology, The Children's Hospital and The Institute of Child Health, Lahore, Pakistan
Abstract
Objective: To determine the effectiveness and safety of Sofosbuvir and Ribavirin combination in treatment-näive children with HCV infection. Study Design: An experimental study. Place and Duration of Study: Gastroentrology, Hepatology Department, The Children's Hospital and The Institute of Child Health, Lahore, from January to December 2016. Methodology: HCV PCR positive treatment-näive patients, 5 to 18 years of age, were enrolled by consecutive nonprobability sampling. Clinical features and investigations including complete blood count, bilirubin, ALT, PT and HCV genotyping were done. All patients were started on Sofosbuvir 400 mg once daily and Ribavirin 10-15 mg/kg/day. Patients were followed on 4-weekly basis. PCR was done after 4 weeks; if positive then again at 12 weeks. End of treatment and 12 weeks post treatment PCR was done in all patients. Total duration of therapy was 24 weeks. Computer program SPSS version 20 was used for data analysis. Results: A total of 35 patients with mean age of 10.24 ±2.80 years, including 22 boys (62.86%), and 13 girls (37.14%) were included. The most common HCV genotype was genotype 3 encountered in 27 (77.15%), followed by genotype 1 in 6 (17.14%), while 2 (5.71%) patients were untypable. Thirty (85.71%) patients achieved rapid virological response while the rest 5 (14.28%) had early virological response. End-of-treatment PCR was negative in all patients. SVR was achieved by 34 (97.14%) patients. The treatment was well tolerated. Headache was observed in 8 (22.86%) patients, which improved spontaneously. Conclusion: Sofosbuvir and Ribavirin combination is highly effective in HCV genotypes 1 and 3 with no major undesirable short-term side effects.
Publication Details
Page(s) 423-426
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 7, Year: 2017

Request the full text from PASTIC

References
BrownellJ,PolyakSJ, 2013.Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer,Clin Cancer Res 19 1347 -52
KhaderiS,ShepherdR,GossJA,LeungDH, 2014.Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation,World J Gastroenterol 20 11281 -6
IslamMS,MiahMR,RoyPK,RahmanO,SiddiqueAB,ChowdhuryJ, 2015.Genotypes of hepatitis C virus infection in Bangladeshi population,Mymensingh Med J 24 143 -51
TahirA,MalikFR,AhmadI,KrishinJ,AkhtarP, 2011.Aetiological factors of chronic liver disease in children,J Ayub Med Coll Abottabad 23 12 -4
SokalEM,BourgoisA,StéphenneX,SilveiraT,PortaG,GardovskaD, 2010.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents,J Hepatol 52 827 -31
WirthS,Pieper-BoustaniH,LangT,BallauffA,KullmerU,GernerP, 2005.Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C,Hepatology 41 1013 -8
DruytsE,ThorlundK,WuP,KantersS,YayaS,CooperCL, 2013.Efficacy and safety of pegylated interferon alfa-2a or alfa2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and metaanalysis,Clin Infect Dis 56 961 -7
SchwarzKB,Gonzalez-PeraltaRP,MurrayKF,MollestonJP,HaberBA,JonasMM, 2011.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C,Gastroenterology 140 450 -8
TomerY, 2010.Hepatitis C and interferon induced thyroiditis,J Autoimmun 34 J322 -6
De FranceschiL,FattovichG,TurriniF,AyiK,BrugnaraC,ManzatoF, 2000.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,Hepatology 31 997 -1004
HerbstDA,ReddyKR, 2013.Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection,Expert Opin Investig Drugs 22 527 -36
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,N Engl J Med 368 34 -44
AzizS,RajperJ,NoorulainW., 2012.Treatment outcome of HCV infected paediatric patients and young adults at Karachi, Pakistan,J Ayub Med Coll Abbottabad 24 56 -8
El-ShabrawiMH,KamalNM, 2013.,World J Gastroenterol 19 7880 -8
MackCL,Gonzalez-PeraltaRP,GuptaN,LeungD,NarkewiczMR,RobertsEA,Nutrition., 2012.NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents,J Pediatr Gastroenterol Nutr 54 838 -55
WiegandJ,SchiefkeI,SteinK,BergT,KulligU,Ende K, 2016.Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders,Hamostaseologie 36 -
AlonsoS,Riveiro-BarcielaM,FernandezI,RincónD,RealY,LlerenaS, 2017.Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort,J Viral Hepat 24 304 -11
MehtaR,KabrawalaM,NandwaniS,TekriwalR,NandaniyaP,ShahM, 2016.Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort,Indian J Gastroenterol 35 459 -64
.Safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection, -
.Safety and efficacy of ledipasvir/sofosbuvir fixed dose combination +/- ribavirin in adolescents and children with chronic HCV-infection, -
0

Citations

0

Downloads

106

Views